Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pro Medicus Limited ( (AU:PME) ) has issued an update.
Pro Medicus Limited has notified the market of the planned issue of 27,986 unquoted performance rights under its employee incentive scheme, scheduled for 3 September 2025. The move underscores the company’s ongoing use of equity-based remuneration to attract and retain key staff, aligning employee incentives with long‑term shareholder value without diluting the quoted share base in the near term.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is an Australian-listed healthcare technology company that develops and supplies medical imaging IT solutions, including radiology information systems and picture archiving and communication systems, primarily serving hospitals, imaging centres and other diagnostic service providers in domestic and international markets.
Average Trading Volume: 171,510
Technical Sentiment Signal: Hold
Current Market Cap: A$21.96B
See more insights into PME stock on TipRanks’ Stock Analysis page.